Moneycontrol PRO
you are here: HomeAuthor

Chiranjivi Chakraborty

Principal Correspondent

Moneycontrol

RBI Monetary Policy | Just like the Fed, an RBI pivot remains elusive for Dalal Street

BUSINESS

RBI Monetary Policy | Just like the Fed, an RBI pivot remains elusive for Dalal Street

The MPC has delivered on the expectations as far as the quantum of the rate hike is concerned as it raised the repo rate to 6.25 percent from 5.9 percent earlier but the pivot on future rate hikes remained elusive

World’s best performing large stock market is set to see record foreign outflows

BUSINESS

World’s best performing large stock market is set to see record foreign outflows

World-beating returns was not enough for foreign investors who pulled out money in large amounts thanks to rising global interest rates and a weakening local currency.

Pivot Powell to China's comeback: 4 global themes that will define investing in 2023

BUSINESS

Pivot Powell to China's comeback: 4 global themes that will define investing in 2023

Equities may see a rout while bonds may emerge bigger in the "year of the yield", predict global investment banks

Why is ICICI Prudential MF doubling down on battered Nykaa?

BUSINESS

Why is ICICI Prudential MF doubling down on battered Nykaa?

The asset manager has snapped up 11.1 million shares in Nykaa’s parent since November 10. That’s roughly 16 percent of the shares sold since the end of the lock-in period for pre-IPO investors.

Fear index for stock market hits 14-month low as investor confidence builds up

BUSINESS

Fear index for stock market hits 14-month low as investor confidence builds up

The volatility gauge has fallen 83 percent from the record high of 86.63 touched on March 24, 2020, which also marked the bottom for the COVID-19 linked crash in the global stock markets.

List of FIIs seeking an out from NSE continues to grow longer

BUSINESS

List of FIIs seeking an out from NSE continues to grow longer

The latest is Morgan Stanley, which is seeking to sell 7-10 lakh shares of NSE through the auction process with a base price of Rs 2,750-2,800. This is at a steep discount of 9-15% over the last available unofficial quote. Also, the number of foreign direct and portfolio investors exiting the exchange itself is increasing.

Buccaneering traders bet Nifty rally has more legs to run on

BUSINESS

Buccaneering traders bet Nifty rally has more legs to run on

In 2022, Indian stocks have outperformed amid continued buying from domestic institutional and retail investors, given the resilient outlook for the economy

Q2 review | IT earnings better than feared but road ahead bumpy

BUSINESS

Q2 review | IT earnings better than feared but road ahead bumpy

The commentary from the management of most major IT companies betrayed a level of uncertainty in their assessment of the demand environment, something not seen in previous earnings calls

Diagnostic giant warns cash-burning startups they have got it all wrong

BUSINESS

Diagnostic giant warns cash-burning startups they have got it all wrong

Backed by deep-pocketed venture capitalists and private equity funds, health technology startups have sprouted in the diagnostics sector over the past five years, hoping to disrupt the existing status quo through low-cost testing procedures

Worries over UPL's bulging debt fail to enthuse investors despite big-bang private equity placement

BUSINESS

Worries over UPL's bulging debt fail to enthuse investors despite big-bang private equity placement

The restructuring exercise has given UPL net proceeds of $259 million, which brokerage firm Prabhudas Lilladher believes will be used towards paring down its debt levels going ahead.

Exclusive | US FDA finds procedural issues at Lupin’s Nagpur injectables plant

BUSINESS

Exclusive | US FDA finds procedural issues at Lupin’s Nagpur injectables plant

Lupin, in an exchange filing on October 30 acknowledging the receipt of the form 482, said that the inspection pertained to pre-approval of its unit two.

Cipla Q2 preview | Consolidated net profit likely to rise 9% YoY

BUSINESS

Cipla Q2 preview | Consolidated net profit likely to rise 9% YoY

In the year-ago quarter, Cipla benefitted from the surge in sales of COVID-19-related drugs

How long will US Fed keep raising the interest rate?

BUSINESS

How long will US Fed keep raising the interest rate?

Economic data over the past few months have showed little sign of stress in the US economy

Sun Pharma’s specialty drugs bet is beginning to pay off

BUSINESS

Sun Pharma’s specialty drugs bet is beginning to pay off

Sun Pharmaceutical’s foray into specialty drugs was in some ways driven by an existential threat posed by rising competition to its generic drug business in the US. In the September quarter, it reported sales of $200 million from specialty drugs in the US, up 27.5 percent YoY

Nykaa’s new CTO aims to embrace crypto, metaverse to boost user engagement

BUSINESS

Nykaa’s new CTO aims to embrace crypto, metaverse to boost user engagement

The former Amazon executive said that in the coming weeks, he will interact with Nykaa's stakeholders to develop more efficient and effective platforms for its customers.

Preview | UPL to see strong growth in Q2 earnings driven by India operations

BUSINESS

Preview | UPL to see strong growth in Q2 earnings driven by India operations

The company will report its quarterly earnings on November 1, just days after it announced a massive restructuring of its business to unlock value.

Q2 Preview | Sun Pharma consolidated net may drop 4% on high R&D costs

BUSINESS

Q2 Preview | Sun Pharma consolidated net may drop 4% on high R&D costs

Sun Pharmaceutical’s consolidated revenues, however, are expected to rise 13.2 percent on a year-on-year basis aided by growth in US specialty products and domestic formulations portfolio

Inflation fight likely to trigger Rs 27,000 crore in losses for PSU refiners in Q2

BUSINESS

Inflation fight likely to trigger Rs 27,000 crore in losses for PSU refiners in Q2

The cumulative net loss of OMCs in the September quarter will be the highest since the June quarter of 2012-13 when they reported a combined loss of Rs 40,536 crore

Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz

BUSINESS

Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz

Dr Reddy’s North American operations will set the tone for the September quarter performance, as likely price erosion will trigger a decline in sales on a year-on-year basis

PharmEasy’s annus horribilis may get worse before it gets better

IPO

PharmEasy’s annus horribilis may get worse before it gets better

The funding winter confronting startups this year owing to surging global interest rates, the capitulation of technology stocks amid fears of a recession in the West and increasing investor dislike for loss-making, cash-burning companies has hit the online pharmacy giant hard.

Earnings, global factors key to a good show this Samvat

BUSINESS

Earnings, global factors key to a good show this Samvat

As investors look forward to the new samvat, many of the same issues will continue to plague global markets including surging inflation, a slowing global economy and heightened geopolitical uncertainties

RIL gains as co to demerge, list Jio Financial Services

BUSINESS

RIL gains as co to demerge, list Jio Financial Services

On October 21, RIL announced that shareholders will get one share of Jio Financial Services for every one share held in the company by them.

ICICI Bank sizzles in muhurat trading post strong Q2 earnings

MARKETS

ICICI Bank sizzles in muhurat trading post strong Q2 earnings

Shares of ICICI Bank have risen 23 percent so far in 2022, outperforming the Nifty Bank index as well as the Nifty 50 index.

Muhurat trading ends on a strong note; here are the factors that drove market

BUSINESS

Muhurat trading ends on a strong note; here are the factors that drove market

Analysts said the Nifty 50 will face tough resistance at 17,850-17,900 levels, and sustainability of the rally will hinge on the index crossing that mark.